title: Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats.
abstract: Considerable evidence indicates that conditioned gaping in rats reflects nausea in this species that does not vomit. A series of experiments evaluated the potential of psychoactive cannabinoid agonists, delta-9-THC and HU-210, and non-psychoactive cannabinoids, Cannabidiol (CBD) and its dimethylheptyl homolog (CBD-dmh), to interfere with the establishment and the expression of conditioned gaping in rats. All agents attenuated both the establishment and the expression of conditioned gaping. Furthermore, the CB1 antagonist, SR-141716, reversed the suppressive effect of HU-210 on conditioned gaping. Finally, SR-141716 potentiated lithium-induced conditioned gaping, suggesting that the endogenous cannabinoid system plays a role in the control of nausea.
authors.affiliation: Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario. lparker@wlu.ca
authors.forename: Linda A
authors.initials: LA
authors.lastname: Parker
authors.forename: Raphael
authors.initials: R
authors.lastname: Mechoulam
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D001362:Avoidance Learning / Q000187:drug effects*; D002185:Cannabidiol / Q000494:pharmacology; D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids / Q000819:agonists / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects*; D013759:Dronabinol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004347:Drug Interactions; D008094:Lithium; D008297:Male; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid / Q000502:physiology; D000077285:Rimonabant; D013649:Taste
chemical_list: D000932:Antiemetics; D063386:Cannabinoid Receptor Agonists; D063387:Cannabinoid Receptor Antagonists; D002186:Cannabinoids; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D002185:Cannabidiol; C007472:3-(1,2-dimethylheptyl)-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran-1-ol; D013759:Dronabinol; D008094:Lithium; C062018:HU 211; D000077285:Rimonabant